南京科佰生物科技有限公司

主營(yíng)產(chǎn)品: atcc代理,ATCC細(xì)胞系,ATCC細(xì)胞株,ATCC細(xì)胞庫(kù)購(gòu)買(mǎi)

11

聯(lián)系電話(huà)

18066071954

您現(xiàn)在的位置: 南京科佰生物科技有限公司>>藥靶細(xì)胞株>>kinase激酶細(xì)胞株>> CBP73202LMNA-NTRK1/BaF3

公司信息

聯(lián)人:
蔣經(jīng)理
話(huà):
4008750250
機(jī):
18066071954
真:
址:
南京市棲霞區(qū)緯地路9號(hào)
編:
210000
個(gè)化:
www.co-bioer.com
網(wǎng)址:
www.cobioer.com/
鋪:
http://m.true-witness.com/st281842/
給他留言
CBP73202LMNA-NTRK1/BaF3
LMNA-NTRK1/BaF3
參考價(jià) 面議
具體成交價(jià)以合同協(xié)議為準(zhǔn)
  • 型號(hào) CBP73202
  • 品牌 cobioer/科佰生物
  • 廠(chǎng)商性質(zhì) 代理商
  • 所在地 南京市

更新時(shí)間:2022-05-05 17:11:46瀏覽次數(shù):663

聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息,謝謝!

【簡(jiǎn)單介紹】
供貨周期 現(xiàn)貨 規(guī)格 T-25 Flask
貨號(hào) CBP73202 應(yīng)用領(lǐng)域 生物產(chǎn)業(yè)
主要用途 僅限科研使用
LMNA-NTRK1/BaF3,母細(xì)胞:BaF3,凍存條件:90% FBS+10% DMSO
【詳細(xì)說(shuō)明】


CBP73202

I. Introduction

Cell Line Name:

LMNA-NTRK1/BaF3

Host Cell:

BA/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS+2ug/ml puromycin

Mycoplasma Status:

Negative


II.Background

NTRK1 rearrangements involve the kinase domain of the NTRK1 gene which includes 17 exons located on chromosome 1q21-22 (Alberti et al. 2003). The frequency of NTRK1 fusions in patients with adenocarcinoma histology is 3.3% of cases (3 out of 91 patients; Vaishnavi et al. 2013).

a In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by ARRY-470, a TRKA/B/C inhibitor (Vaishnavi et al. 2013).

b In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by lestaurtinib, a FLT3/TRKA inhibitor (Vaishnavi et al. 2013).

c A patient with non-small cell lung cancer harboring an MPRIP-NTRK1 fusion mutation was treated with crizotinib, which has activity against TRKA in addition to ALK, MET and ROS1 (Vaishnavi et al. 2013). The patient demonstrated a small radiographic decrease in tumor size but experienced disease progression after three months (Vaishnavi et al. 2013)


III. Representative Data

1. WB of LMNA-NTRK1/BaF3 expression

CBP73202 WB.jpg



2. Sanger of LMNA-NTRK1/BaF3 expression


CBP73202 sanger.jpg

Figure 2. Sanger Sequencing of LMNA-NTRK1/BaF3


3. Anti-proliferation assay

CBP73202 fig.jpg

Figure 3. Anti-proliferation assay of two reference compounds on the LMNA-NTRK1/BaF3 Stable Cell Line





產(chǎn)品對(duì)比 產(chǎn)品對(duì)比 二維碼 在線(xiàn)交流

掃一掃訪(fǎng)問(wèn)手機(jī)商鋪

對(duì)比框

在線(xiàn)留言